DUBLIN, Calif., April 22 — Microchip Biotechnologies, Inc. (MBI) announces that it has entered into a multi-patent license agreement with GE Healthcare that significantly enhances MBI’s intellectual property portfolio supporting the development of lab-on-a-chip devices. The patents cover design and methods for creating integrated fluidic microchip devices. “Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices,” said Dr. Stevan Jovanovich, President and CEO of MBI. “Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics.” California-based MBI will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays. Microfluidics technologies are essential for development of lab-on-a-chip devices for DNA analysis and molecular diagnostics. Microfluidic devices are smaller, faster and cheaper than the laboratory benchtop instruments that they are designed to replace, and are exquisitely suited for clinical and forensic systems used at the bedside or in the field. About Microchip Biotechnologies Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI’s proprietary “NanoBioProcessor(TM) platform and associated “Microscale-on-Chip-Valves” (MOV(TM)). More details can be found on the Company’s website: http://www.microchipbiotech.com.